Drug intelligence / Profile preview

ITI-1771

Development stage: Preclinical
Lead developer: Immunomic Therapeutics
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Small Molecules, Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ITI-1771 is a therapeutic vaccine in preclinical development by Immunomic Therapeutics. It is designed to treat cancers driven by the expression of cytomegalovirus (CMV), with potential indications including colorectal cancer, glioblastoma (GBM), and triple negative breast cancer. The vaccine utilizes a self-amplifying RNA (saRNA) platform to stimulate an immune response against CMV-expressing tumor cells[1][2][3].

Beyond the preview

Go deeper on ITI-1771.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITI-1771.

Explore the full profile